Timothy R. Rebbeck, PhD

Timothy R. Rebbeck, PhD

Contact Information

Office Phone Number

+1 (617) 632-6128

Fax

+1 (617) 632-2250

Biography

Timothy R. Rebbeck, PhD

Professor Rebbeck joined the Dana-Farber Cancer Institute and the Harvard TH Chan School in 2015 as the Vincent L. Gregory, Jr. Professor of Cancer Prevention. Professor Rebbeck serves as the director for the Zhu Family Center for Global Cancer Prevention Harvard TH Chan School of Public Health and the Center for Global Health Equity at Dana-Farber Cancer Institute. He directs large, multicenter studies and international consortia that have identified genetic, molecular, and epidemiological factors associated with cancer risk, outcomes, and disparities. He leads the international Men of African Descent and Carcinoma of the Prostate (MADCaP) network and has led a number of consortia studying hereditary cancer risk and prevention. He also directs the NCI-funded African cancer STARS training program that supports career development for African cancer researchers and project managers. Dr. Rebbeck has mentored over 65 trainees, most of whom hold positions in academia. He has been continuously funded by the NIH since 1994.

Researcher

Physician

Vincent L. Gregory, Jr. Professor of Cancer Prevention, Harvard TH Chan School of Public Health and Dana-Farber Cancer Institute
Director, Zhu Family Center for Global Cancer Prevention Harvard TH Chan School of Public Health
Division of Population Sciences, Dana Farber Cancer Institute

Recent Awards

  • 2010: Spirit of Empowerment Award, FORCE: Facing Our Risk of Cancer Empowered.
  • 2011: Landon Foundation-AACR Innovator Award for International Collaboration in Cancer Research.
  • 2011-2016: Fulbright Specialist to Africa, United States Department of State.
  • 2017: Joseph F. Fraumeni, Jr. Distinguished Achievement Award, American Society for Preventive Oncology.
  • 2020: ASCO-American Cancer Society Award and Lecture, American Society of Clinical Oncology.

Research

    Professor Rebbeck’s research has contributed to an understanding of the causes and prevention of cancer, with an emphasis on cancer genetics, prostate cancer disparities, and global health equity.

     

    Professor Rebbeck has directed multiple molecular epidemiologic studies and international consortia to identify and characterize genes and other risk factors that are candidates for involvement in cancer etiology. His research involves translating this knowledge to cancer prevention and early detection. These include:

    “Study of Clinical Outcomes, Risk and Ethnicity” (SCORE): a molecular epidemiological study to evaluate risk factors for prostate cancer, with a focus on genetic markers of etiology and outcomes in African, African American, and European American men. 

    “Men of African Descent and Carcinoma of the Prostate” (MADCaP) involves centers in North America, Europe, and Africa to address the global epidemic of prostate cancer in the African diaspora. MADCaP is engaged in a recently funded Specialized Program of Research Excellence for Cancer Health Disparities to develop precision interception approaches for aggressive prostate cancer in African American men. 

    Studies of Hereditary Cancer Susceptibility and Prevention: Using large multicenter databases, I have identified genetic causes of hereditary and non-hereditary cancers, as well as the use of genetic information to inform precision interventions aimed at cancer prevention. This work has led to practice-changing approaches to cancer risk and mortality reduction in carriers of BRCA1 and BRCA2 mutation carriers. I have also contributed to knowledge of modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers to optimize risk and prevention strategies for breast, ovary, and prostate cancers

    Publications

      • ASO Visual Abstract: Associations Between Neighborhood-Level Income and Triple-Negative Breast Cancer in a Majority-Minority Population. Ann Surg Oncol. 2024 Feb; 31(2):1029-1030. View in: Pubmed

      • Uncovering the genetic architecture and evolutionary roots of androgenetic alopecia in African men. bioRxiv. 2024 Jan 15. View in: Pubmed

      • Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population. Blood Adv. 2024 Jan 11. View in: Pubmed

      • Prostate cancer screening in African American men: a review of the evidence. J Natl Cancer Inst. 2024 Jan 10; 116(1):34-52. View in: Pubmed

      • Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study. Cancer Med. 2023 Dec 29. View in: Pubmed

      • Associations Between Neighborhood-Level Income and Triple-Negative Breast Cancer in a Majority-Minority Population. Ann Surg Oncol. 2024 Feb; 31(2):988-996. View in: Pubmed

      • Racial differences in knowledge, attitudes, and sources of information about germline cancer genetic testing in the U.S.A.: An analysis of the health information National Trends Survey System. Prev Med. 2024 Jan; 178:107779. View in: Pubmed

      • Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet. 2023 Dec; 55(12):2065-2074. View in: Pubmed

      • Advancing Social and Environmental Research in Cancer Registries Using Geomasking for Address-Level Data. Cancer Epidemiol Biomarkers Prev. 2023 11 01; 32(11):1485-1489. View in: Pubmed

      • Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction. medRxiv. 2023 Oct 30. View in: Pubmed

      • Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program. Cancer Causes Control. 2024 Mar; 35(3):509-521. View in: Pubmed

      • Heterogeneous genetic architectures and evolutionary genomics of prostate cancer in Sub-Saharan Africa. Res Sq. 2023 Oct 12. View in: Pubmed

      • Cancer equity for those impacted by mass incarceration. J Natl Cancer Inst. 2023 10 09; 115(10):1128-1131. View in: Pubmed

      • Global viewpoints: updates on prostate cancer in Sub-Saharan Africa. BJU Int. 2024 01; 133(1):6-13. View in: Pubmed

      • Influence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals. Am J Epidemiol. 2023 09 01; 192(9):1485-1498. View in: Pubmed

      • The role of community outreach and engagement in evaluation of NCI Cancer Center Support Grants. Cancer Causes Control. 2024 Jan; 35(1):73-75. View in: Pubmed

      • Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2023 08 01; 32(8):1120-1123. View in: Pubmed

      • Disparities in Travel-Related Barriers to Accessing Health Care From the 2017 National Household Travel Survey. JAMA Netw Open. 2023 07 03; 6(7):e2325291. View in: Pubmed

      • Understanding inequities in precision oncology diagnostics. Nat Cancer. 2023 06; 4(6):787-794. View in: Pubmed

      • Translational Epidemiology: Genetic Ancestry in Breast Cancer: What Is the Role of Genetic Ancestry and Socioeconomic Status in Triple-Negative Breast Cancer? Adv Surg. 2023 09; 57(1):1-14. View in: Pubmed

      • Risk prediction models for endometrial cancer: development and validation in an international consortium. J Natl Cancer Inst. 2023 05 08; 115(5):552-559. View in: Pubmed

      • Germline Testing Around the Globe: Challenges in Different Practice Settings. Am Soc Clin Oncol Educ Book. 2023 May; 43:e390522. View in: Pubmed

      • Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Cancer Epidemiol Biomarkers Prev. 2023 04 03; 32(4):487-495. View in: Pubmed

      • Referral practices of recent graduate and experienced physiotherapists working in Australian primary care for people with musculoskeletal conditions. Musculoskelet Sci Pract. 2023 04; 64:102745. View in: Pubmed

      • Variant-specific Mendelian Risk Prediction Model. bioRxiv. 2023 Mar 08. View in: Pubmed

      • Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. Eur Urol. 2023 07; 84(1):13-21. View in: Pubmed

      • Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospital systems serving health disparity populations. Urol Oncol. 2023 05; 41(5):252.e9-252.e17. View in: Pubmed

      • Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men. Cancer Epidemiol Biomarkers Prev. 2022 Dec 05; 31(12):2192-2198. View in: Pubmed

      • Risk factors for endometrial cancer in Black women. Cancer Causes Control. 2023 May; 34(5):421-430. View in: Pubmed

      • Distance to Multidisciplinary Team Clinic in Gaborone, Botswana, and Stage at Cervical Cancer Presentation for Women Living With and Without HIV. JCO Glob Oncol. 2022 11; 8:e2200183. View in: Pubmed

      • Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa. PLoS One. 2022; 17(10):e0276050. View in: Pubmed

      • Leveraging Molecular Diagnostic Technologies to Close the Global Cancer Pathology Gap. JCO Glob Oncol. 2022 Oct; 8:e2200182. View in: Pubmed

      • Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa. Genome Biol. 2022 09 13; 23(1):194. View in: Pubmed

      • What Geohistory Can Teach Us About Fundamental Causes of Health Inequities. Health Equity. 2022; 6(1):691-695. View in: Pubmed

      • Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol. 2022 10; 19(10):656-673. View in: Pubmed

      • Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease. J Natl Cancer Inst. 2022 Sep 02. View in: Pubmed

      • Relative impact of genetic ancestry and neighborhood socioeconomic status on all-cause mortality in self-identified African Americans. PLoS One. 2022; 17(8):e0273735. View in: Pubmed

      • Evaluating the geographic distribution of cervical cancer patients presenting to a multidisciplinary gynecologic oncology clinic in Gaborone, Botswana. PLoS One. 2022; 17(8):e0271679. View in: Pubmed

      • Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. Elife. 2022 07 08; 11. View in: Pubmed

      • Proceedings of the fifth international Molecular Pathological Epidemiology (MPE) meeting. Cancer Causes Control. 2022 Aug; 33(8):1107-1120. View in: Pubmed

      • The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer. NPJ Precis Oncol. 2022 Jun 17; 6(1):39. View in: Pubmed

      • Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies. Cancer Epidemiol Biomarkers Prev. 2022 06 01; 31(6):1139-1145. View in: Pubmed

      • Race-specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990-2017. Cancer Med. 2022 Nov; 11(22):4354-4365. View in: Pubmed

      • Reply to V. Fallet et al. J Clin Oncol. 2022 08 01; 40(22):2509-2510. View in: Pubmed

      • Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncol. 2022 06; 23(6):e251-e312. View in: Pubmed

      • Racial Disparities in Prostate Cancer: Evaluation of Diet, Lifestyle, Family History, and Screening Patterns. Cancer Epidemiol Biomarkers Prev. 2022 05 04; 31(5):982-990. View in: Pubmed

      • Toward Equitable Access to Tertiary Cancer Care in Rwanda: A Geospatial Analysis. JCO Glob Oncol. 2022 05; 8:e2100395. View in: Pubmed

      • The distinct impacts of race and genetic ancestry on health. Nat Med. 2022 05; 28(5):890-893. View in: Pubmed

      • Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. Eur Urol Open Sci. 2022 Jun; 40:19-26. View in: Pubmed

      • Current and projected number of years of life lost due to prostate cancer: A global study. Prostate. 2022 08; 82(11):1088-1097. View in: Pubmed

      • A Framework for Promoting Diversity, Equity, and Inclusion in Genetics and Genomics Research. JAMA Health Forum. 2022 04; 3(4). View in: Pubmed

      • Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer. Breast Cancer Res Treat. 2022 Jun; 193(3):625-635. View in: Pubmed

      • Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022 May; 9(5):e340-e349. View in: Pubmed

      • Retrospective analysis to describe trends in first-ever prostate-specific antigen (PSA) testing for primary healthcare facilities in the Gauteng Province, South Africa, between 2006 and 2016. BMJ Open. 2022 03 21; 12(3):e050646. View in: Pubmed

      • Early detection of cancer. Science. 2022 03 18; 375(6586):eaay9040. View in: Pubmed

      • Impact of neighborhood socioeconomic status, income segregation, and greenness on blood biomarkers of inflammation. Environ Int. 2022 04; 162:107164. View in: Pubmed

      • Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysis. Prostate Cancer Prostatic Dis. 2022 09; 25(3):547-552. View in: Pubmed

      • American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence. Gastrointest Endosc. 2022 05; 95(5):827-854.e3. View in: Pubmed

      • ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022 05; 95(5):817-826. View in: Pubmed

      • Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. J Clin Oncol. 2022 05 10; 40(14):1529-1541. View in: Pubmed

      • A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. Eur Urol. 2022 05; 81(5):458-462. View in: Pubmed

      • Prostate Cancer Screening, Diagnostic, Treatment Procedures and Costs in Sub-Saharan Africa: A Situational Analysis. Cancer Control. 2022 Jan-Dec; 29:10732748221084932. View in: Pubmed

      • DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. JNCI Cancer Spectr. 2022 02; 6(1). View in: Pubmed

      • Regular Aspirin Use and Mortality in Patients with Multiple Myeloma. Cancer Epidemiol Biomarkers Prev. 2022 02; 31(2):479-485. View in: Pubmed

      • Overall and central obesity and prostate cancer risk in African men. Cancer Causes Control. 2022 Feb; 33(2):223-239. View in: Pubmed

      • Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study. Prostate. 2021 12; 81(16):1402-1410. View in: Pubmed

      • Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021 12; 41(12):1387-1397. View in: Pubmed

      • Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genet. 2021 11; 258-259:61-68. View in: Pubmed

      • Clinical and sociodemographic factors associated with late stage cervical cancer diagnosis in Botswana. BMC Womens Health. 2021 07 06; 21(1):267. View in: Pubmed

      • Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. Cancer Cell. 2021 08 09; 39(8):1042-1044. View in: Pubmed

      • The rising burden of cancer in low- and middle-Human Development Index countries. Cancer. 2021 08 15; 127(16):2864-2866. View in: Pubmed

      • Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. J Natl Cancer Inst. 2021 06 01; 113(6):719-726. View in: Pubmed

      • Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. Cancer. 2021 08 01; 127(15):2714-2723. View in: Pubmed

      • A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate. 2021 07; 81(10):683-693. View in: Pubmed

      • Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. NPJ Precis Oncol. 2021 May 03; 5(1):35. View in: Pubmed

      • Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2. Eur Urol Focus. 2021 Jul; 7(4):722-732. View in: Pubmed

      • Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position. Cancer. 2021 07 15; 127(14):2525-2534. View in: Pubmed

      • Corrigendum to "Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations" [Gynecologic Oncology 156 (2020) 363-376]. Gynecol Oncol. 2021 May; 161(2):636. View in: Pubmed

      • From COVID-19 to cancer, watching social determinants decide life: When will we stop spectating? J Natl Med Assoc. 2021 Aug; 113(4):436-439. View in: Pubmed

      • Susceptibility-Associated Genetic Variation in NEDD9 Contributes to Prostate Cancer Initiation and Progression. Cancer Res. 2021 07 15; 81(14):3766-3776. View in: Pubmed

      • Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021 Jan 13; 13(2). View in: Pubmed

      • Prostate cancer age-standardised incidence increase between 2006 and 2016 in Gauteng Province, South Africa: A laboratory data-based analysis. S Afr Med J. 2020 Dec 14; 111(1):26-32. View in: Pubmed

      • Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 04; 81(4):325-330. View in: Pubmed

      • Discovering novel driver mutations from pan-cancer analysis of mutational and gene expression profiles. PLoS One. 2020; 15(11):e0242780. View in: Pubmed

      • Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. Int J Cancer. 2021 05 01; 148(9):2068-2078. View in: Pubmed

      • TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer. Prostate. 2021 02; 81(2):109-117. View in: Pubmed

      • Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiol Biomarkers Prev. 2021 01; 30(1):217-228. View in: Pubmed

      • Neighborhood greenness and burden of non-communicable diseases in Sub-Saharan Africa: A multi-country cross-sectional study. Environ Res. 2021 05; 196:110397. View in: Pubmed

      • Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 01 01; 27(1):320-329. View in: Pubmed

      • Body Mass Index, Chemotherapy-Related Weight Changes, and Disease-Free Survival in Haitian Women With Nonmetastatic Breast Cancer. JCO Glob Oncol. 2020 10; 6:1656-1665. View in: Pubmed

      • Geospatial evaluation of trade-offs between equity in physical access to healthcare and health systems efficiency. BMJ Glob Health. 2020 10; 5(10). View in: Pubmed

      • Rethinking Environmental Carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2020 10; 29(10):1870-1875. View in: Pubmed

      • Racial Differences in Genomic Profiling of Prostate Cancer. N Engl J Med. 2020 09 10; 383(11):1083-1085. View in: Pubmed

      • Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. Int J Cancer. 2021 01 15; 148(2):307-319. View in: Pubmed

      • Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 2020 08 01; 6(8):1218-1230. View in: Pubmed

      • Patient Characteristics and Outcomes of Nonmetastatic Breast Cancer in Haiti: Results from a Retrospective Cohort. Oncologist. 2020 09; 25(9):e1372-e1381. View in: Pubmed

      • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811. View in: Pubmed

      • A Custom Genotyping Array Reveals Population-Level Heterogeneity for the Genetic Risks of Prostate Cancer and Other Cancers in Africa. Cancer Res. 2020 07 01; 80(13):2956-2966. View in: Pubmed

      • Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis. JNCI Cancer Spectr. 2020 Aug; 4(4):pkaa029. View in: Pubmed

      • The association between neighborhood greenness and incidence of lethal prostate cancer: A prospective cohort study. Environ Epidemiol. 2020 Apr; 4(2):e091. View in: Pubmed

      • The contribution of residential greenness to mortality among men with prostate cancer: a registry-based cohort study of Black and White men. Environ Epidemiol. 2020 Apr; 4(2):e087. View in: Pubmed

      • Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients. Clin Cancer Res. 2020 04 15; 26(8):1915-1923. View in: Pubmed

      • Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020 02 17; 10(2):19. View in: Pubmed

      • Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. PLoS Genet. 2020 02; 16(2):e1008641. View in: Pubmed

      • Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer. Cancer Med. 2020 04; 9(7):2379-2389. View in: Pubmed

      • Cancer Progress and Priorities: Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):267-277. View in: Pubmed

      • Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations. Gynecol Oncol. 2020 02; 156(2):363-376. View in: Pubmed

      • Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 04 01; 126(7):1407-1412. View in: Pubmed

      • Cancer in sub-Saharan Africa. Science. 2020 01 03; 367(6473):27-28. View in: Pubmed

      • Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020 02 15; 126(4):717-724. View in: Pubmed

      • Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638. View in: Pubmed

      • Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. Eur Urol. 2020 02; 77(2):158-166. View in: Pubmed

      • The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Hum Mutat. 2019 11; 40(11):e1-e23. View in: Pubmed

      • BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019 10; 40(10):1781-1796. View in: Pubmed

      • Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer. 2019 10 01; 125(19):3338-3346. View in: Pubmed

      • Elucidating Under-Studied Aspects of the Link Between Obesity and Multiple Myeloma: Weight Pattern, Body Shape Trajectory, and Body Fat Distribution. JNCI Cancer Spectr. 2019 Sep; 3(3):pkz044. View in: Pubmed

      • Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192. View in: Pubmed

      • Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol. 2019 07; 2(4):405-412. View in: Pubmed

      • Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med. 2019 05 23; 380(21):2070-2072. View in: Pubmed

      • Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2019 Aug; 30(8):799-811. View in: Pubmed

      • Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015. JAMA Netw Open. 2019 05 03; 2(5):e193759. View in: Pubmed

      • Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Jul 15; 25(14):4290-4299. View in: Pubmed

      • Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364. View in: Pubmed

      • Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. JAMA. 2019 Feb 19; 321(7):704-706. View in: Pubmed

      • Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol. 2019 06; 75(6):1038-1040. View in: Pubmed

      • A practical approach to adjusting for population stratification in genome-wide association studies: principal components and propensity scores (PCAPS). Stat Appl Genet Mol Biol. 2018 12 04; 17(6). View in: Pubmed

      • AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. Cancer Prev Res (Phila). 2018 12; 11(12):735-778. View in: Pubmed

      • Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study. Cancer Epidemiol Biomarkers Prev. 2019 03; 28(3):570-577. View in: Pubmed

      • When Is Enough, Enough? When Are More Observational Epidemiologic Studies Needed to Resolve a Research Question: Illustrations Using Biomarker-Cancer Associations. Cancer Epidemiol Biomarkers Prev. 2019 02; 28(2):239-247. View in: Pubmed

      • Estimate of the incidence of bladder cancer in Africa: A systematic review and Bayesian meta-analysis. Int J Urol. 2019 01; 26(1):102-112. View in: Pubmed

      • Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell. 2018 10 08; 34(4):549-560.e9. View in: Pubmed

      • Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood. Cold Spring Harb Perspect Med. 2018 09 04; 8(9). View in: Pubmed

      • Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). J Glob Oncol. 2018 09; 4:1-12. View in: Pubmed

      • Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate. J Glob Oncol. 2018 09; 4:1-14. View in: Pubmed

      • Estimates of Cancer Incidence in Ethiopia in 2015 Using Population-Based Registry Data. J Glob Oncol. 2018 09; 4:1-11. View in: Pubmed

      • Identification of nine new susceptibility loci for endometrial cancer. Nat Commun. 2018 08 09; 9(1):3166. View in: Pubmed

      • Cancer incidence and mortality rates and trends in Trinidad and Tobago. BMC Cancer. 2018 Jul 04; 18(1):712. View in: Pubmed

      • Precision Prevention and Early Detection of Cancer: Fundamental Principles. Cancer Discov. 2018 07; 8(7):803-811. View in: Pubmed

      • Collaborations in gynecologic oncology education and research in low- and middle- income countries: Current status, barriers and opportunities. Gynecol Oncol Rep. 2018 Aug; 25:65-69. View in: Pubmed

      • The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control. 2018 07; 29(7):685-697. View in: Pubmed

      • Editorial: The Fruits of the Genomic Revolution. Cancer Epidemiol Biomarkers Prev. 2018 04; 27(4):362. View in: Pubmed

      • Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. Br J Cancer. 2018 04; 118(7):1013-1019. View in: Pubmed

      • Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018 05; 39(5):593-620. View in: Pubmed

      • Genetic Hitchhiking and Population Bottlenecks Contribute to Prostate Cancer Disparities in Men of African Descent. Cancer Res. 2018 05 01; 78(9):2432-2443. View in: Pubmed

      • Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women. Oncotarget. 2018 May 18; 9(38):25025-25033. View in: Pubmed

      • Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. Cancer. 2018 03 01; 124(5):952-959. View in: Pubmed

      • Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424. View in: Pubmed

      • Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13 anatomic sites. Oncotarget. 2017 Oct 17; 8(49):85680-85691. View in: Pubmed

      • Strengthening care and research for women's cancers in Sub-Saharan Africa. Gynecol Oncol Rep. 2017 Aug; 21:109-113. View in: Pubmed

      • Emerging proteomics biomarkers and prostate cancer burden in Africa. Oncotarget. 2017 Jun 06; 8(23):37991-38007. View in: Pubmed

      • Breastfeeding and Endometrial Cancer Risk: An Analysis From the Epidemiology of Endometrial Cancer Consortium. Obstet Gynecol. 2017 06; 129(6):1059-1067. View in: Pubmed

      • Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250. View in: Pubmed

      • Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiol Biomarkers Prev. 2017 07; 26(7):1016-1026. View in: Pubmed

      • Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev. 2017 04; 26(4):553-560. View in: Pubmed

      • Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 04 01; 77(7):1510-1541. View in: Pubmed

      • A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness. PLoS One. 2017; 12(3):e0174548. View in: Pubmed

      • Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2017 02; 28(2):167-176. View in: Pubmed

      • African Organization for Research and Training in Cancer: position and vision for cancer research on the African Continent. Infect Agent Cancer. 2016; 11:63. View in: Pubmed

      • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016 11 11; 18(1):112. View in: Pubmed

      • Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet. 2016 11 01; 25(21):4835-4846. View in: Pubmed

      • Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncol. 2016 Nov 01; 2(11):1434-1440. View in: Pubmed

      • Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017 01; 161(1):117-134. View in: Pubmed

      • Predicting Prostate Cancer Recurrence After Radical Prostatectomy. Prostate. 2017 02; 77(3):291-298. View in: Pubmed

      • Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A. 2016 09 27; 113(39):10750-8. View in: Pubmed

      • Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet. 2016 Sep 04. View in: Pubmed

      • Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. Semin Radiat Oncol. 2017 01; 27(1):3-10. View in: Pubmed

      • The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer. BMC Cancer. 2016 07 29; 16:557. View in: Pubmed

      • Defining Priorities for Reducing Disparities in Cancer Mortality. Cancer Epidemiol Biomarkers Prev. 2016 Apr; 25(4):570-2. View in: Pubmed

      • GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer. Hum Mol Genet. 2016 06 15; 25(12):2612-2620. View in: Pubmed

      • Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15. View in: Pubmed

      • Race, Ethnicity, Psychosocial Factors, and Telomere Length in a Multicenter Setting. PLoS One. 2016; 11(1):e0146723. View in: Pubmed

      • Oncologic Care and Pathology Resources in Africa: Survey and Recommendations. J Clin Oncol. 2016 Jan 01; 34(1):20-6. View in: Pubmed

      • Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. J Clin Oncol. 2016 Jan 01; 34(1):91-101. View in: Pubmed

      • Distinct microbiological signatures associated with triple negative breast cancer. Sci Rep. 2015 Oct 15; 5:15162. View in: Pubmed

      • Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 2015 Oct 12; 28(4):529-540. View in: Pubmed

      • Correction: Cancer Incidence following Expansion of HIV Treatment in Botswana. PLoS One. 2015; 10(9):e0138742. View in: Pubmed

      • Genetic variants in hypothalamic-pituitary-adrenal axis genes and breast cancer risk in Caucasians and African Americans. Int J Mol Epidemiol Genet. 2015; 6(1):33-40. View in: Pubmed

      • Cancer Incidence following Expansion of HIV Treatment in Botswana. PLoS One. 2015; 10(8):e0135602. View in: Pubmed

      • RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. J Natl Cancer Inst. 2015 Sep; 107(9). View in: Pubmed

      • Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol. 2015 Sep 01; 33(25):2789-96. View in: Pubmed

      • Individual- and neighborhood-level education influences the effect of obesity on prostate cancer treatment failure after prostatectomy. Cancer Causes Control. 2015 Sep; 26(9):1329-37. View in: Pubmed

      • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016 05; 141(2):386-401. View in: Pubmed

      • Building a funded research program in cancer health disparities: considerations for young investigators. Cancer Epidemiol Biomarkers Prev. 2015 May; 24(5):882-5. View in: Pubmed

      • An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015 Apr 25; 17:61. View in: Pubmed

      • Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61. View in: Pubmed

      • Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev. 2015 Jul; 24(7):1121-9. View in: Pubmed

      • Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One. 2015; 10(4):e0120020. View in: Pubmed

      • Inherited variation at MC1R and histological characteristics of primary melanoma. PLoS One. 2015; 10(3):e0119920. View in: Pubmed

      • Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet. 2015 Apr; 134(4):439-50. View in: Pubmed

      • Development and validation of a melanoma risk score based on pooled data from 16 case-control studies. Cancer Epidemiol Biomarkers Prev. 2015 May; 24(5):817-24. View in: Pubmed

      • Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb; 47(2):164-71. View in: Pubmed

      • Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Dec 31; 16(6):3416. View in: Pubmed

      • Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Causes Control. 2015 Feb; 26(2):287-296. View in: Pubmed

      • Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 2014 Dec 23; 16(6):3419. View in: Pubmed

      • Inherited variation at MC1R and ASIP and association with melanoma-specific survival. Int J Cancer. 2015 Jun 01; 136(11):2659-67. View in: Pubmed

      • Precision prevention of cancer. Cancer Epidemiol Biomarkers Prev. 2014 Dec; 23(12):2713-5. View in: Pubmed

      • African-american race is a predictor of seminal vesicle invasion after radical prostatectomy. Clin Genitourin Cancer. 2015 Apr; 13(2):e65-72. View in: Pubmed

      • Genetic variants in anti-Mullerian hormone and anti-Mullerian hormone receptor genes and breast cancer risk in Caucasians and African Americans. Int J Mol Epidemiol Genet. 2014; 5(3):145-51. View in: Pubmed

      • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16. View in: Pubmed

      • Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406. View in: Pubmed

      • African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urol Oncol. 2015 Feb; 33(2):70.e15-22. View in: Pubmed

      • Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol. 2014 Oct; 21(5):7496-506. View in: Pubmed

      • AACR Cancer Progress Report 2014. Clin Cancer Res. 2014 Oct 01; 20(19 Suppl):S1-S112. View in: Pubmed

      • Supervised multi-view canonical correlation analysis (sMVCCA): integrating histologic and proteomic features for predicting recurrent prostate cancer. IEEE Trans Med Imaging. 2015 Jan; 34(1):284-97. View in: Pubmed

      • Radiogenomics: radiobiology enters the era of big data and team science. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):709-13. View in: Pubmed

      • Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer. 2015 Mar 01; 136(5):1210-7. View in: Pubmed

      • Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab. 2014 Aug 05; 20(2):306-319. View in: Pubmed

      • Cigarettes, genetic background, and menopausal timing: the presence of single nucleotide polymorphisms in cytochrome P450 genes is associated with increased risk of natural menopause in European-American smokers. Menopause. 2014 Jul; 21(7):694-701. View in: Pubmed

      • Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014 Jun; 106(6):dju091. View in: Pubmed

      • Co-occurring gland angularity in localized subgraphs: predicting biochemical recurrence in intermediate-risk prostate cancer patients. PLoS One. 2014; 9(5):e97954. View in: Pubmed

      • Academic bigotry. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1445-6. View in: Pubmed

      • Exome-wide association study of endometrial cancer in a multiethnic population. PLoS One. 2014; 9(5):e97045. View in: Pubmed

      • Gene-environment interactions between JAZF1 and occupational and household lead exposure in prostate cancer among African American men. Cancer Causes Control. 2014 Jul; 25(7):869-79. View in: Pubmed

      • DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256. View in: Pubmed

      • Building capacity for sustainable research programmes for cancer in Africa. Nat Rev Clin Oncol. 2014 May; 11(5):251-9. View in: Pubmed

      • Exome sequencing of filaggrin and related genes in African-American children with atopic dermatitis. J Invest Dermatol. 2014 Aug; 134(8):2272-2274. View in: Pubmed

      • Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. J Allergy Clin Immunol. 2014 Mar; 133(3):784-9. View in: Pubmed

      • General practitioners' knowledge of whiplash guidelines improved with online education. Aust Health Rev. 2013 Nov; 37(5):688-94. View in: Pubmed

      • Genome-wide association study of endometrial cancer in E2C2. Hum Genet. 2014 Feb; 133(2):211-24. View in: Pubmed

      • Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):308-14. View in: Pubmed

      • Association of progesterone receptor gene (PGR) variants and breast cancer risk in African American women. Breast Cancer Res Treat. 2013 Jun; 139(3):833-43. View in: Pubmed

      • Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013 Jul 10; 31(20):2607-18. View in: Pubmed

      • Obesity-susceptibility loci and the tails of the pediatric BMI distribution. Obesity (Silver Spring). 2013 Jun; 21(6):1256-60. View in: Pubmed

      • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013 Apr; 45(4):371-84, 384e1-2. View in: Pubmed

      • Improvement of pathology in sub-Saharan Africa. Lancet Oncol. 2013 Apr; 14(4):e152-7. View in: Pubmed

      • Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. Lancet Oncol. 2013 Apr; 14(4):e142-51. View in: Pubmed

      • Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212. View in: Pubmed

      • Relationship of early-onset baldness to prostate cancer in African-American men. Cancer Epidemiol Biomarkers Prev. 2013 Apr; 22(4):589-96. View in: Pubmed

      • Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis. 2013 Jul; 34(7):1520-8. View in: Pubmed

      • Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013 Apr; 22(4):508-16. View in: Pubmed

      • Bridging the gap between biologic, individual, and macroenvironmental factors in cancer: a multilevel approach. Cancer Epidemiol Biomarkers Prev. 2013 Apr; 22(4):485-95. View in: Pubmed

      • Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer. 2013; 2013:560857. View in: Pubmed

      • What stresses men? Predictors of perceived stress in a population-based multi-ethnic cross sectional cohort. BMC Public Health. 2013 Feb 06; 13:113. View in: Pubmed

      • Gender- and ethnic-specific associations with obesity: individual and neighborhood-level factors. J Natl Med Assoc. 2013; 105(2):173-82. View in: Pubmed

      • Reliability and validity of genotyping filaggrin null mutations. J Dermatol Sci. 2013 Apr; 70(1):67-8. View in: Pubmed

      • Analyzing genetic association studies with an extended propensity score approach. Stat Appl Genet Mol Biol. 2012 Oct 19; 11(5). View in: Pubmed

      • Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men. Prostate Cancer. 2012; 2012:798634. View in: Pubmed

      • Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Res Treat. 2012 Nov; 136(1):295-302. View in: Pubmed

      • The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J Allergy Clin Immunol. 2012 Oct; 130(4):912-7. View in: Pubmed

      • A genome-wide association study of breast cancer in women of African ancestry. Hum Genet. 2013 Jan; 132(1):39-48. View in: Pubmed

      • Cancer prevention for global health: a report from the ASPO International Cancer Prevention Interest Group. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1606-10. View in: Pubmed

      • Evolutionary history and adaptation from high-coverage whole-genome sequences of diverse African hunter-gatherers. Cell. 2012 Aug 03; 150(3):457-69. View in: Pubmed

      • Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol. 2012 Aug 15; 176(4):269-78. View in: Pubmed

      • A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1362-70. View in: Pubmed

      • Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer. 2012 Jun 05; 106(12):2016-24. View in: Pubmed

      • Joint effects of smoking and gene variants involved in sex steroid metabolism on hot flashes in late reproductive-age women. J Clin Endocrinol Metab. 2012 Jun; 97(6):E1032-42. View in: Pubmed

      • Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8. View in: Pubmed

      • Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer. 2012 Mar; 11(1):69-75. View in: Pubmed

      • The good news about cancer in developing countries--pathology answers the call. Lancet. 2012 Feb 25; 379(9817):712. View in: Pubmed

      • Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis. 2012 Apr; 33(4):835-40. View in: Pubmed

      • Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Apr; 21(4):645-57. View in: Pubmed

      • Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res. 2012 Feb 20; 14(1):R33. View in: Pubmed

      • Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat. 2012 Apr; 33(4):690-702. View in: Pubmed

      • A founder mutation in LEPRE1 carried by 1.5% of West Africans and 0.4% of African Americans causes lethal recessive osteogenesis imperfecta. Genet Med. 2012 May; 14(5):543-51. View in: Pubmed

      • Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):552-6. View in: Pubmed

      • Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):134-47. View in: Pubmed

      • Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection. Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):53-60. View in: Pubmed

      • Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Res Treat. 2012 Feb; 132(1):341-5. View in: Pubmed

      • Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2011; 13(6):R110. View in: Pubmed

      • A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011 Oct 30; 43(12):1210-4. View in: Pubmed

      • Relationship of obesity, androgen receptor genotypes and biochemical failure after radical prostatectomy. Prostate. 2012 Jun 15; 72(9):984-90. View in: Pubmed

      • Prostate cancer severity associations with neighborhood deprivation. Prostate Cancer. 2011; 2011:846263. View in: Pubmed

      • Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. Carcinogenesis. 2011 Dec; 32(12):1862-6. View in: Pubmed

      • Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet. 2011 Dec 01; 20(23):4732-47. View in: Pubmed

      • Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Hum Mol Genet. 2011 Nov 15; 20(22):4491-503. View in: Pubmed

      • Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011 Sep 01; 71(17):5792-805. View in: Pubmed

      • Replication of GWAS "Hits" by Race for Breast and Prostate Cancers in European Americans and African Americans. Front Genet. 2011; 2:37. View in: Pubmed

      • Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1690-702. View in: Pubmed

      • Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis. 2011 Sep; 32(9):1361-5. View in: Pubmed

      • Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer. 2012 May; 58(5):695-700. View in: Pubmed

      • Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011 Jun; 43(6):570-3. View in: Pubmed

      • Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? J Clin Oncol. 2011 May 20; 29(15_suppl):1501. View in: Pubmed

      • Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet. 2011 Nov; 130(5):685-99. View in: Pubmed

      • Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2011 Aug 15; 20(16):3304-21. View in: Pubmed

      • National Cancer Institute Prostate Cancer Genetics Workshop. Cancer Res. 2011 May 15; 71(10):3442-6. View in: Pubmed

      • Obtaining DNA in the mail from a national sample of children with a chronic non-fatal illness. J Invest Dermatol. 2011 Aug; 131(8):1765-7. View in: Pubmed

      • Decision tree-based modeling of androgen pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2011 Jun; 20(6):1146-55. View in: Pubmed

      • Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res. 2011 Apr 05; 13(2):R40. View in: Pubmed

      • Where were you in November 1991? Cancer Epidemiol Biomarkers Prev. 2011 Apr; 20(4):567-8. View in: Pubmed

      • Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. Br J Cancer. 2011 Apr 12; 104(8):1356-61. View in: Pubmed

      • Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2011 May; 20(5):1032-8. View in: Pubmed

      • Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res. 2011 Mar 01; 17(5):1075-81. View in: Pubmed

      • The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One. 2011 Feb 08; 6(2):e16756. View in: Pubmed

      • Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res. 2011 Jan 20; 13(1):R8. View in: Pubmed

      • Dissecting the within-Africa ancestry of populations of African descent in the Americas. PLoS One. 2011 Jan 06; 6(1):e14495. View in: Pubmed

      • Capitalizing on admixture in genome-wide association studies: a two-stage testing procedure and application to height in African-Americans. Front Genet. 2011; 2. View in: Pubmed

      • Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis. 2011 Mar; 32(3):331-5. View in: Pubmed

      • Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 01; 70(23):9742-54. View in: Pubmed

      • Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2010; 12(6):R102. View in: Pubmed

      • Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev. 2011 Jan; 20(1):23-32. View in: Pubmed

      • Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet. 2010 Oct 28; 6(10):e1001183. View in: Pubmed

      • Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2859-68. View in: Pubmed

      • Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations. LDI Issue Brief. 2010 Oct-Nov; 16(2):1-4. View in: Pubmed

      • A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010 Oct; 42(10):885-92. View in: Pubmed

      • Effect of hormone metabolism genotypes on steroid hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition. Menopause. 2010 Sep-Oct; 17(5):1026-34. View in: Pubmed

      • Context-dependent effects of genome-wide association study genotypes and macroenvironment on time to biochemical (prostate specific antigen) failure after prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010 Sep; 19(9):2115-23. View in: Pubmed

      • Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 01; 304(9):967-75. View in: Pubmed

      • Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU Int. 2011 Feb; 107(3):466-70. View in: Pubmed

      • Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res. 2010; 12(3):R28. View in: Pubmed

      • Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer. 2010 May 15; 116(10):2416-28. View in: Pubmed

      • Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res. 2010; 12(3):R26. View in: Pubmed

      • Fostering transdisciplinary science. Cancer Epidemiol Biomarkers Prev. 2010 May; 19(5):1149-50. View in: Pubmed

      • Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2010 Jul 15; 19(14):2886-97. View in: Pubmed

      • Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010 Nov; 124(2):441-51. View in: Pubmed

      • Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203. View in: Pubmed

      • Dietary intake of Senegalese adults. Nutr J. 2010 Feb 18; 9:7. View in: Pubmed

      • Germline mutations and polymorphisms in the origins of cancers in women. J Oncol. 2010; 2010:297671. View in: Pubmed

      • A special issue on tobacco. Cancer Epidemiol Biomarkers Prev. 2009 Dec; 18(12):3139. View in: Pubmed

      • A propensity score approach to correction for bias due to population stratification using genetic and non-genetic factors. Genet Epidemiol. 2009 Dec; 33(8):679-90. View in: Pubmed

      • Evaluation of group genetic ancestry of populations from Philadelphia and Dakar in the context of sex-biased admixture in the Americas. PLoS One. 2009 Nov 25; 4(11):e7842. View in: Pubmed

      • Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2010 Jul; 122(1):281-5. View in: Pubmed

      • Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009 Oct; 41(10):1116-21. View in: Pubmed

      • Null results in brief: meeting a need in changing times. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2347. View in: Pubmed

      • Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15; 69(14):5801-10. View in: Pubmed

      • Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol. 2009 Aug 01; 170(3):269-79. View in: Pubmed

      • Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A. 2009 Jun 16; 106(24):9761-6. View in: Pubmed

      • Occult ovarian cancers at the time of risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. J Clin Oncol. 2009 May 20; 27(15_suppl):1508. View in: Pubmed

      • Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol. 2009 Jun; 38(3):814-30. View in: Pubmed

      • Clique-finding for heterogeneity and multidimensionality in biomarker epidemiology research: the CHAMBER algorithm. PLoS One. 2009; 4(3):e4862. View in: Pubmed

      • A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer. 2009 Jan 15; 124(2):420-8. View in: Pubmed

      • Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009 Jan 21; 101(2):80-7. View in: Pubmed

      • Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):242-7. View in: Pubmed

      • Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. 2009; 11(5):R76. View in: Pubmed

      • Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis. 2009 Feb; 30(2):269-74. View in: Pubmed

      • Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):2903-5. View in: Pubmed

      • Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila). 2008 Nov; 1(6):393-5. View in: Pubmed

      • Joint effects of inflammation and androgen metabolism on prostate cancer severity. Int J Cancer. 2008 Sep 15; 123(6):1385-9. View in: Pubmed

      • Common 8q24 sequence variations are associated with Asian Indian advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2431-5. View in: Pubmed

      • Cancer Epidemiology Biomarkers & Prevention. A note from the new Editor-in-Chief. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2203-4. View in: Pubmed

      • Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol. 2008 Sep 01; 26(25):4151-9. View in: Pubmed

      • The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res. 2008 Sep 01; 68(17):7006-14. View in: Pubmed

      • U-statistics-based tests for multiple genes in genetic association studies. Ann Hum Genet. 2008 Nov; 72(Pt 6):821-33. View in: Pubmed

      • Association of donor inflammation- and apoptosis-related genotypes and delayed allograft function after kidney transplantation. Am J Kidney Dis. 2008 Aug; 52(2):331-9. View in: Pubmed

      • Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2008; 10(4):108. View in: Pubmed

      • Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and Health Disparities. Am J Public Health. 2008 Sep; 98(9):1608-15. View in: Pubmed

      • Clinical and genetic risk factors of self-reported penicillin allergy. J Allergy Clin Immunol. 2008 Jul; 122(1):152-8. View in: Pubmed

      • No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Res Treat. 2009 May; 115(1):185-92. View in: Pubmed

      • Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol. 2008 Jun; 15(3):4056-64. View in: Pubmed

      • Analysis of the RNASEL/HPC1, and macrophage scavenger receptor 1 in Asian-Indian advanced prostate cancer. Urology. 2008 Aug; 72(2):456-60. View in: Pubmed

      • Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008 Apr; 82(4):937-48. View in: Pubmed

      • Ancestry estimation and correction for population stratification in molecular epidemiologic association studies. Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17(3):471-7. View in: Pubmed

      • Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test. 2008 Mar; 12(1):81-91. View in: Pubmed

      • Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008 Mar 10; 26(8):1331-7. View in: Pubmed

      • Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can J Urol. 2008 Feb; 15(1):3872-82. View in: Pubmed

      • A study of PSA values in an unselected sample of Senegalese men. Can J Urol. 2008 Feb; 15(1):3883-5. View in: Pubmed

      • In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort". J Clin Oncol. 2007 Dec 10; 25(35):5675-7. View in: Pubmed

      • Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer. 2007 Dec; 7(11):875-82. View in: Pubmed

      • Association of hypertension genotypes and decline in renal function after kidney transplantation. Transplantation. 2007 Nov 27; 84(10):1240-7. View in: Pubmed

      • RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007 Dec; 81(6):1186-200. View in: Pubmed

      • Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008 Feb; 37(1):120-32. View in: Pubmed

      • Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol. 2007 Nov; 178(5):1939-44; discussion 1945. View in: Pubmed

      • Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol. 2007 Dec 15; 166(12):1392-9. View in: Pubmed

      • AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1416-21. View in: Pubmed

      • Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1318-20. View in: Pubmed

      • Genetic association studies of cancer: where do we go from here? Cancer Epidemiol Biomarkers Prev. 2007 May; 16(5):864-5. View in: Pubmed

      • A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer. 2007 Apr 01; 120(7):1523-8. View in: Pubmed

      • Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomarkers Prev. 2007 Mar; 16(3):444-50. View in: Pubmed

      • Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol. 2007 Feb; 19(1):27-30. View in: Pubmed

      • CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol. 2007 May; 127(5):1234-43. View in: Pubmed

      • Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control. 2007 Apr; 18(3):295-304. View in: Pubmed

      • Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood. 2007 Apr 15; 109(8):3409-16. View in: Pubmed

      • New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival. Cancer Epidemiol Biomarkers Prev. 2006 Nov; 15(11):2042-6. View in: Pubmed

      • Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol. 2006 Oct 15; 164(8):775-86. View in: Pubmed

      • Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst. 2006 Sep 20; 98(18):1311-20. View in: Pubmed

      • Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res. 2006 Sep 15; 66(18):9330-7. View in: Pubmed

      • Conquering cancer disparities: new opportunities for cancer epidemiology, biomarker, and prevention research. Cancer Epidemiol Biomarkers Prev. 2006 Sep; 15(9):1569-71. View in: Pubmed

      • The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev. 2006 Aug; 15(8):1520-5. View in: Pubmed

      • Multi-center prospective analysis of risk-reducing salpingo-oophorectomy to prevent BRCA-associated breast and ovarian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1003. View in: Pubmed

      • Members of the glutathione (GSH) and ABC-transporter families are associated with clinical outcomes in patients with diffuse large B-cell lymphoma (DLCL). J Clin Oncol. 2006 Jun 20; 24(18_suppl):10035. View in: Pubmed

      • Genetics, epidemiology, and cancer disparities: is it black and white? J Clin Oncol. 2006 May 10; 24(14):2164-9. View in: Pubmed

      • Inherited genetic markers and cancer outcomes: personalized medicine in the postgenome era. J Clin Oncol. 2006 May 01; 24(13):1972-4. View in: Pubmed

      • Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2437-43. View in: Pubmed

      • A prospective cohort study of health outcomes following whiplash associated disorders in an Australian population. Inj Prev. 2006 Apr; 12(2):93-8. View in: Pubmed

      • A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol. 2006 Jun; 35(3):756-64. View in: Pubmed

      • Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006 Mar; 7(3):223-9. View in: Pubmed

      • Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Compr Canc Netw. 2006 Feb; 4(2):177-82. View in: Pubmed

      • Evaluating bias due to population stratification in epidemiologic studies of gene-gene or gene-environment interactions. Cancer Epidemiol Biomarkers Prev. 2006 Jan; 15(1):124-32. View in: Pubmed

      • Ethnicity, ancestry, and race in molecular epidemiologic research. Cancer Epidemiol Biomarkers Prev. 2005 Nov; 14(11 Pt 1):2467-71. View in: Pubmed

      • Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis. 2006 Mar; 27(3):610-8. View in: Pubmed

      • The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis. 2006 Mar; 27(3):599-605. View in: Pubmed

      • Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005 Oct 20; 23(30):7491-6. View in: Pubmed

      • Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005 Oct 19; 97(20):1507-15. View in: Pubmed

      • Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 01; 23(31):7804-10. View in: Pubmed

      • Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics: a case-series study. Breast Cancer Res. 2005; 7(6):R909-21. View in: Pubmed

      • Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol. 2005 Aug 20; 23(24):5552-9. View in: Pubmed

      • MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst. 2005 Jul 06; 97(13):998-1007. View in: Pubmed

      • Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics. 2005 Jun; 15(6):393-8. View in: Pubmed

      • Bias correction with a single null marker for population stratification in candidate gene association studies. Hum Hered. 2005; 59(3):165-75. View in: Pubmed

      • Genetics, disparities, and prostate cancer. LDI Issue Brief. 2005 May-Jun; 10(7):1-4. View in: Pubmed

      • Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):949-57. View in: Pubmed

      • Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 2005 Mar 15; 65(6):2482-7. View in: Pubmed

      • Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors. Int J Cancer. 2005 Jan 20; 113(3):471-4. View in: Pubmed

      • Genetic variation and cancer: improving the environment for publication of association studies. Cancer Epidemiol Biomarkers Prev. 2004 Dec; 13(12):1985-6. View in: Pubmed

      • CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 2004 Nov 15; 64(22):8461-7. View in: Pubmed

      • Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control. 2004 Nov; 15(9):957-65. View in: Pubmed

      • Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers. J Med Genet. 2004 Nov; 41(11):e120. View in: Pubmed

      • Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev. 2004 Sep; 13(9):1543-6. View in: Pubmed

      • Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2004 Sep; 13(9):1473-9. View in: Pubmed

      • Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet. 2004 Aug; 5(8):589-97. View in: Pubmed

      • Evaluating bias due to population stratification in case-control association studies of admixed populations. Genet Epidemiol. 2004 Jul; 27(1):14-20. View in: Pubmed

      • Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. Int J Cancer. 2004 Jun 10; 110(2):266-70. View in: Pubmed

      • SNPs, haplotypes, and cancer: applications in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2004 May; 13(5):681-7. View in: Pubmed

      • Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach. Cancer Epidemiol Biomarkers Prev. 2004 May; 13(5):808-19. View in: Pubmed

      • Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62. View in: Pubmed

      • Biomarkers of inherited susceptibility and cancer. IARC Sci Publ. 2004; (157):91-103. View in: Pubmed

      • CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2003 Jul; 122(2):240-4. View in: Pubmed

      • Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese men. Urology. 2003 May; 61(5):987-92. View in: Pubmed

      • Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J Med Genet. 2003 Apr; 40(4):e34. View in: Pubmed

      • Group sequential methods and sample size savings in biomarker-disease association studies. Genetics. 2003 Mar; 163(3):1215-9. View in: Pubmed

      • Epidemiological approaches to the identification of cancer predisposition genes. Methods Mol Biol. 2003; 222:309-25. View in: Pubmed

      • Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen. 2003; 42(4):299-305. View in: Pubmed

      • Population frequencies of single nucleotide polymorphisms (SNPs) in immuno-modulatory genes. Hum Hered. 2003; 55(4):171-8. View in: Pubmed

      • Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res. 2002 Nov 15; 62(22):6651-8. View in: Pubmed

      • Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer. 2002 Nov; 38 Suppl 6:S15-7. View in: Pubmed

      • Inherited genotype and prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):945-52. View in: Pubmed

      • Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002 Sep 18; 94(18):1365-72. View in: Pubmed

      • Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer. 2002 Sep 01; 95(5):969-81. View in: Pubmed

      • Differential bone marrow aspirate DNA yields from commercial extraction kits. Leukemia. 2002 Sep; 16(9):1865-6. View in: Pubmed

      • P gene as an inherited biomarker of human eye color. Cancer Epidemiol Biomarkers Prev. 2002 Aug; 11(8):782-4. View in: Pubmed

      • Pilot study: does the white coat influence research participation? IRB. 2002 Jul-Aug; 24(4):6-8. View in: Pubmed

      • Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23; 346(21):1616-22. View in: Pubmed

      • CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. Hum Mol Genet. 2002 May 15; 11(11):1327-32. View in: Pubmed

      • The contribution of inherited genotype to breast cancer. Breast Cancer Res. 2002; 4(3):85-9. View in: Pubmed

      • BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol. 2002 Feb 15; 20(4):994-9. View in: Pubmed

      • A polymorphism in the agouti signaling protein gene is associated with human pigmentation. Am J Hum Genet. 2002 Mar; 70(3):770-5. View in: Pubmed

      • Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk. Environ Mol Mutagen. 2002; 39(2-3):228-34. View in: Pubmed

      • Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered. 2002; 54(1):13-21. View in: Pubmed

      • Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001 Dec; 10(12):1239-48. View in: Pubmed

      • Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct; 11(7):635-8. View in: Pubmed

      • Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 2001 Jul 15; 61(14):5420-4. View in: Pubmed

      • Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res. 2001 Jun; 7(6):1688-97. View in: Pubmed

      • Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2001 May; 10(5):509-13. View in: Pubmed

      • An intronic variant in PTEN is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2001 Mar; 10(3):277-8. View in: Pubmed

      • BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol. 2001 Feb 15; 19(4):992-1000. View in: Pubmed

      • Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry. 2001 Feb 06; 40(5):1159-70. View in: Pubmed

      • Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics. 2001 Feb; 11(1):57-68. View in: Pubmed

      • Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001 Jan; 115(1):85-98. View in: Pubmed

      • The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking. Cancer Epidemiol Biomarkers Prev. 2000 Dec; 9(12):1329-34. View in: Pubmed

      • Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol. 2000 Dec; 35(6):526-30. View in: Pubmed

      • BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res. 2000 Nov; 6(11):4259-64. View in: Pubmed

      • Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2000 Nov 01; 18(21 Suppl):100S-3S. View in: Pubmed

      • Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet. 2000 Oct; 67(4):1014-9. View in: Pubmed

      • Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol. 2000 May; 18(9):1980-95. View in: Pubmed

      • Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 2000 Mar 15; 60(6):1626-30. View in: Pubmed

      • More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 2000 Jan 05; 92(1):76. View in: Pubmed

      • Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer. 1999 Dec 01; 86(11 Suppl):2493-501. View in: Pubmed

      • Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999 Sep 01; 91(17):1475-9. View in: Pubmed

      • Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ Health Perspect. 1999 Jul; 107(7):517-20. View in: Pubmed

      • Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet. 1999 May; 64(5):1371-7. View in: Pubmed

      • Glutathione S-transferase-mu (GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1999 Apr; 8(4 Pt 1):283-7. View in: Pubmed

      • Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation. 1999 Mar 23; 99(11):1422-5. View in: Pubmed

      • Polymorphisms in PTEN in breast cancer families. J Med Genet. 1999 Feb; 36(2):94-6. View in: Pubmed

      • Validation of a melanoma prognostic model. Arch Dermatol. 1998 Dec; 134(12):1597-601. View in: Pubmed

      • Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13176-81. View in: Pubmed

      • Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML) Blood. 1998 Oct 01; 92(7):2600-2. View in: Pubmed

      • Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998 Aug 19; 90(16):1225-9. View in: Pubmed

      • MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children. J Pediatr Hematol Oncol. 1998 Jul-Aug; 20(4):299-308. View in: Pubmed

      • Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998 May 20; 90(10):761-6. View in: Pubmed

      • p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res. 1998 May-Jun; 18(3B):2095-9. View in: Pubmed

      • BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998 Apr; 178(4):670-7. View in: Pubmed

      • Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar; 62(3):676-89. View in: Pubmed

      • Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat. 1998; 12(4):289. View in: Pubmed

      • Hereditary neuralgic amyotrophy: evidence for genetic homogeneity and mapping to chromosome 17q25. Hum Genet. 1997 Dec; 101(3):277-83. View in: Pubmed

      • Molecular genetic analysis of familial neuroblastoma. Eur J Cancer. 1997 Oct; 33(12):1923-8. View in: Pubmed

      • Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997 Sep; 6(9):733-43. View in: Pubmed

      • BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997 May 15; 336(20):1409-15. View in: Pubmed

      • Utility of linked markers in genetic counseling: estimation of carrier risks in X-linked ocular albinism. Am J Med Genet. 1997 May 02; 70(1):58-66. View in: Pubmed

      • Evaluation of genotype data in clinical risk assessment: methods and application to BRCA1, BRCA2, and N-acetyl transferase-2 genotypes in breast cancer. Genet Test. 1997-1998; 1(3):157-64. View in: Pubmed

      • Defining etiologic heterogeneity in breast cancer using genetic biomarkers. Prog Clin Biol Res. 1997; 396:53-61. View in: Pubmed

      • Variability in loss of constitutional heterozygosity across loci and among individuals: association with candidate genes in ductal breast carcinoma. Mol Carcinog. 1996 Nov; 17(3):117-25. View in: Pubmed

      • Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov; 2(11):1179-83. View in: Pubmed

      • Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet. 1996 Sep; 59(3):547-53. View in: Pubmed

      • Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res. 1996 Aug 01; 56(15):3421-5. View in: Pubmed

      • Probability of having hypertension: effects of sex, history of hypertension in parents, and other risk factors. J Clin Epidemiol. 1996 Jul; 49(7):727-34. View in: Pubmed

      • Mapping of hereditary neuralgic amyotrophy (familial brachial plexus neuropathy) to distal chromosome 17q. Neurology. 1996 Apr; 46(4):1128-32. View in: Pubmed

      • Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet. 1996 Mar; 12(3):309-11. View in: Pubmed

      • Risk prediction with linked markers: pedigree analysis. Am J Med Genet. 1995 Oct 23; 59(1):24-32. View in: Pubmed

      • Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA. 1995 Feb 15; 273(7):577-85. View in: Pubmed

      • Using loss of heterozygosity data in affected pedigree member linkage tests. Genet Epidemiol. 1995; 12(4):339-50. View in: Pubmed

      • Phenotypic variability in X-linked ocular albinism: relationship to linkage genotypes. Am J Hum Genet. 1994 Sep; 55(3):484-96. View in: Pubmed

      • Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. Cancer Epidemiol Biomarkers Prev. 1994 Sep; 3(6):511-4. View in: Pubmed

      • Somatic allele loss in genetic linkage analysis of cancer. Genet Epidemiol. 1994; 11(5):419-29. View in: Pubmed

      • A single-gene explanation for the probability of having idiopathic talipes equinovarus. Am J Hum Genet. 1993 Nov; 53(5):1051-63. View in: Pubmed

      • Sodium-lithium countertransport genotype and the probability of hypertension in adults. Hypertension. 1993 Oct; 22(4):560-8. View in: Pubmed

      • Sodium-lithium countertransport and probability of hypertension in Caucasians 47 to 89 years old. Hypertension. 1992 Dec; 20(6):841-50. View in: Pubmed

      • Genetic and environmental explanations for the distribution of sodium-lithium countertransport in pedigrees from Rochester, MN. Am J Hum Genet. 1991 Jun; 48(6):1092-104. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Dana Building Room 1101 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Dana Building Room 1101 Boston, MA 02215
      Get Direction
      42.3374, -71.1082